More Meds on the Way

There are more than 10 dozen anti-HIV drugs in the developmental pipeline that pharmaceutical manufacturers and other research institutions are working on; that's roughly 50% more than were being worked on a year ago. The entry inhibitor category continues to show strong promise with 40 candidates'15 more than this time last year.

Entry Inhibitors
(Medication Name, Stage of Development, Developer)
' 15D, Preclinical, National Cancer Institute
' 15K, Preclinical, National Cancer Institute
' AK602, Phase I, Kumamoto University
' AMD3451 CCR5-CXCR4 blocker), Preclinical, Anormed
' Betulinic acid derivatives; Preclinical; University of North Carolina, Duke University, Vanderbilt University
' BMS-378806 (gp120 blocker), Phase I, Bristol-Myers Squibb
' CCR5mAb004 (CCR5 blocker), Preclinical, Human Genome Sciences
' D5 (artificial gp41 blocker), Preclinical, Merck
' DP-178 (fusion inhibitor), Preclinical, Weizmann Institute
' GBV-C (virus increases chemokines, including CCR5 blockers), Preclinical, University of Iowa
' gp41 inhibitor, Preclinical, New York Blood Center
' gp41 inhibitor, Preclinical, Locus Pharmaceuticals
' gp120-gp41 disulfide bond; Preclinical; Amsterdam Mathematical Center, Cornell University, University of Illinois at Chicago
' IC9564, Preclinical, Duke University
' Indolicidin, Preclinical,National Institutes of Health
' KD-247 (CCR5 blocker), Preclinical, Kumamoto University
' KRH-2731 (CXCR4 blocker), Preclinical, Kureha
''KRH-3140 (CXCR4 blocker), Preclinical, Kureha
' KRH-3955 (CXCR4 blocker), Preclinical, Kureha
''Maraviroc/UK-427 (CCR5 blocker), Phase III, Pfizer
''MDX-010, Preclinical, Medarex
' Monoclonal FAbs (gp41 blocker), Preclinical, National Institutes of Health
''NB-2 (gp41 blocker), Preclinical, Shibo and Kumar
' NB-64 (gp41 blocker), Preclinical, Shibo and Kumar
''NSC 13778 (gp120 blocker), Preclinical, SAIC-National Cancer Institute
' PRO-140 (monoclonal antibody), Phase I, Progenics
' Pyrrolidine (CCR5 blocker), Preclinical, Merck
' RANTES analogs (CCR5 blockers), Preclinical, University of Geneva
' RC-112, Preclinical, CDC's AIDS, STD, and TB Laboratory Research
' Retrocyclin-1, Preclinical, CDC's AIDS, STD, and TB Laboratory Research
' Sifuvirtide, Preclinical, Fusogen
' SP-01 A, Preclinical, Samaritan
' SP-10, Preclinical, Samaritan
' TAK-652 (CCR5 blocker), Preclinical, Takeda
' TNX-355 (monoclonal antibody), Phase II, Tanox and Biogen
' TR-999, Preclinical, Trimeris and Roche
' TR-1144, Preclinical, Trimeris and Roche
' UMIST, Preclinical, Genetic Innovation Network
' Vicriviroc/SCH-D (CCR5 blocker), Phase II, Schering Plough
' Zinc finger protein nucleases (CCR5 blockers), Preclinical, Sangamo Biosciences

Integrase Inhibitors
(Medication Name, Stage of Development, Developer)
' AVX-I, Preclinical, Avexa
' Beta-diketo acids, Preclinical, University of Parma and University of Sassari
' Carbazole derivative, Preclinical, Japan's National Institute of Infectious Diseases
' GSK-810871, Preclinical, GlaxoSmithKline
' Indolicidin, Preclinical, National Cancer Institute
' GS-9137 (JTK-303), Phase II, Gilead Sciences and Japan Tobacco
' ITI-367, Preclinical, George Washington University
' L-second generation, Preclinical, Merck
' MK-0518, Phase III, Merck
' Monophores, Preclinical, Sunesis
' Mycelium integrasone (fungal polyketide), Preclinical, Merck
' PL-2500, Preclinical, Procyon Biopharma
' Styrylquinoline derivatives, Preclinical, BioAlliance Pharma
' Theophyline, Preclinical, Thomas Jefferson University
' V-165, Preclinical, Rega Institute

Maturation Inhibitors
(Medication Name, Stage of Development, Developer)
' Alpha HGA, Phase I, Tripep
' Betulinic acid derivatives (entry, maturation inhibitors); Preclinical; University of North Carolina, Duke University, Vanderbilt University
' Chloroquine, Preclinical, Catholic University of Rome
' enJS56A1, Preclinical, University of Georgia
' PA-457 (capsid inhibitor), Phase II, Vitex
' RPI-MN, Preclinical, ReceptoPharm
' UK-201844, Preclinical, Pfizer

Nonnucleoside Reverse Transcriptase Inhibitors
(Medication Name, Stage of Development, Developer)
' BILR 355 BS, Phase I/II, Boehringer-Ingelheim
' DOT (dioxolane thymidine), Phase I, University of Georgia
' GS9148, Preclinical, Gilead Sciences
' GSK-695634, Phase I, GlaxoSmithKline
' MIV-170, Preclinical, Medivir
' NVP C-8 substituent, Preclinical, Boehringer-Ingelheim
' Oligodeoxi-nucleotides, Preclinical, University of Zurich
' PBO-15c (pyrrolobenzoxazepinone), Preclinical, University of Siena
' Phenylthiazoylamines, Preclinical, Yale University
' Pyridinone derivatives, Preclinical, Rutgers University
' Quinolones, Preclinical, Wellcome Trust
' S-DABO derivatives, Preclinical, China's Fudan University
' SMP-610, Preclinical, Advanced Life Sciences
' SMP-717, Preclinical, Advanced Life Sciences
' Thiazol derivatives, Preclinical, Japan's Institute for Virus Research
' TMC-125 (etravirine), Phase III, Tibotec and Johnson & Johnson
' TMC-278 (diarylpyrimidine or DAPY), Phase II, Tibotec
' Tricyclic NNRTI, Preclinical, Bristol-Myers Squibb

Nucleoside Reverse Transcriptase Inhibitors
(Medication Name, Stage of Development, Developer)
' 4-Ed4T, Preclinical, Kagoshima University
' AVX754, Phase I/II, Avexa
' BPH-218, Preclinical, University of Pittsburgh
' Branched 3 primers, Preclinical, University of Illinois
' Compound X, Preclinical, Tibotec
' D-FDOC, Preclinical, Emory University
' Dinucleoside polyphosphates, Preclinical, University of Miami
' DOT-TP, Preclinical, Emory University
' dTTP, Preclinical, University of Rochester
' E2-FdA, Preclinical, Kumamoto University
' Elvucitabine (ACH-126), Phase II, Achillion
' Herpesvirus saimiri, Preclinical, Temple University
' KMMP05, Preclinical, National Cancer Institute
' KP-1461, Phase I/II, Koronis
' Racivir, Phase I/II, Pharmasset
' Stampidine, Preclinical, Parker Hughes Institute
' Thiovir, Preclinical, Adventrx
' Triol, Preclinical, Cruz Foundation

Protease Inhibitors
(Medication Name, Stage of Development, Developer)
' A-681799, Preclinical, Abbott Laboratories
' Beta-lactams, Preclinical, University of Debrecen
' Brecanavir (GSK-640385), Phase II, GlaxoSmithKline
' GRL-02031, Preclinical, Kumamoto University
' PPL-100, Preclinical, Procyon Biopharma
' SPI-256, Preclinical, Sequoia
' UIC02031, Preclinical, Kumamoto University

Others
(Medication Name, Stage of Development, Developer)
' Alpha-v integrins, Preclinical, irsiCaixa Foundation and Merck
' BL-1050 (regulatory protein inhibitor), Preclinical, BioLine Rx
' CDK inhibitor, Preclinical, Gilead Sciences
' CNI-1493 (rev inhibitor), Preclinical, Heinrich Pette Institute
' Curcumin/diferuloylmethane (tat inhibitor), Preclinical, Jawaharlal Nehru Center
' Cycloamides, Phase I, University of Illinois
' Glycodendrimers (lipid raft carbohydrates), Preclinical, Penn State University
' HRG214 (caprine IgG), Preclinical, Virionyx
' IM (CDK9 inhibitor), Preclinical, Institute of Human Virology
' KU-55933 (ATM kinase inhibitor), Preclinical, Kudos Pharma
' MDI-P (electrolyzed free radical), Preclinical, Medical Discoveries
' Mifepristone (glucocorticoid antagonist), Phase I, University of Pittsburgh
' Oxadiazols (nuclear localization viral matrix blockers), Preclinical, International Therapeutics
' Poly acrylic acid, Preclinical, Chinese Academy of Science
' Resveretrol (Egr1 gene activator), Preclinical, National Cancer Institute
' Rev inhibitors, Preclinical, National Institutes of Health
' RPI (nicotinic acetylcholine receptor blocker), Preclinical, NutraPharma
' RSC-1838, Preclinical, GlaxoSmithKline and Shionogi
' RWJ67567 (p38 inhibitor), Preclinical, University of Pennsylvania and Johnson & Johnson
' siRNA constructs (rev/tat inhibitors), Preclinical, Beckman Institute
' siRNA molecule, Preclinical, CombiMatrix
' TRIM5-alpha (capsid inhibitor), Preclinical, Dana Farber Cancer Institute-NIAID